CABALETTA BIO INC
1 day chart
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell for the treatment of patients with autoimmune diseases. Its CABA platform encompasses two approaches: chimeric antigen receptor T cells for autoimmunity (CARTA) and chimeric autoantibody receptor T cells (CAART). Its product candidates include CABA-201, DSG3-CAART, DSG3/1-CAART, MuSK-CAART and PLA2R-CAART. Its lead product candidate, CABA-201, is designed to achieve transient depletion of all CD19-positive B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by naive healthy B cells. Its lead product candidate for the CAART strategy, DSG3-CAART, is designed to enable specific cytotoxicity toward B cells autoreactive to DSG3. Its next PV product candidate, DSG3/1-CAART, is being designed to target DSG3 and/or DSG1 autoreactive B cell receptors on pathogenic B cells that cause mcPV.
Buy US stocks in Australia starting with CABA. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CABA
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.